If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 151 - 160 of 275
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Patients with Mature B-Cell Malignancies
Objective
A Phase 1 Study if SGR-1505 in Patients with B-Cell Malignancies
Protocol No
SCHRODINGER-SGR-1505-101
Categories
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Objective
The purpose of this part of this study is to compare the effects, good and/or bad, of the standard treatment (radiation therapy and cisplatin) with one of the experimental treatments chosen from the first part of the study (either radiation therapy and docetaxel or radiation therapy, cetuximab, and docetaxel) to find out which is better.
Protocol No
RTOG-1216
Categories
A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Objective
Comparing drugs for advanced non-small cell lung cancer with EGFR and MET gene changes
Protocol No
SWOG-S1900G
Categories
A Randomized, Open-Label Study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison with Atezolizumab Plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Objective
A randomized study to compare Atezolizumab plus Chemotherapy vs HLX10 plus Chemo in ES-SCLC
Protocol No
SHB-HLX10-005-SCLC301-E
Categories
A First-in-Human, Phase 1/2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors
Objective
BOXR1030 T Cells in Advanced GPC3-Positive Solid Tumors
Protocol No
SOTIO-BOXR1030
Categories
PROmoting CLinicAl TrIal EngageMent for Pancreatic Cancer App Study (PROCLAIM Study)
Objective
Promoting CT Engagement for Pancreatic Cancer With App (PROCLAIM)
Protocol No
UNC-LCCC2234-PROCLAIM
Categories
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Objective
A First-in-Human, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors
Protocol No
XILIO-XTX301-01-02-001
Categories
Cancer,
Gynecologic Cancers,
Esophagus,
Thoracic Cancers,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Kidney,
Other Skin,
Pancreas/Liver,
Other Urologic,
Prostate and Urologic Cancers,
Stomach,
Skin Cancers,
Head and Neck Cancers,
Esophagus,
Gastrointestinal Cancers,
Sarcoma,
Breast Cancers
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Objective
Phase 1/2, Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Protocol No
TAKEDA-TAK-280-1501
A Phase 2, Open-Label Study Evaluating STRO-002, an Anti-Folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1
Objective
Study of luveltamab tazevibulin in adults with previously treated advanced or metastatic NSCLC
Protocol No
SUTRO-REFRAME-L1
Categories
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Objective
A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH
Protocol No
SWOG-MYELOMATCH
Categories